The immunology of COVID-19: is immune modulation an option for treatment?

J Zhong, J Tang, C Ye, L Dong - The Lancet Rheumatology, 2020 - thelancet.com
In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly spread
globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths …

Strategies toward rheumatoid arthritis therapy; the old and the new

M Abbasi, MJ Mousavi, S Jamalzehi… - Journal of cellular …, 2019 - Wiley Online Library
Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and
nonsteroidal anti‐inflammatory drugs (NSAIDs), predominantly used for controlling the pain …

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Y Pu, L Li, H Peng, L Liu, D Heymann… - Nature Reviews …, 2023 - nature.com
Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis

AR Phull, B Nasir, I ul Haq, SJ Kim - Chemico-biological interactions, 2018 - Elsevier
There are numerous extra-and intra-cellular processes involved in the production of reactive
oxygen species (ROS). Augmented ROS generation can cause the damage of biomolecules …

Graves' ophthalmopathy

RS Bahn - New England Journal of Medicine, 2010 - Mass Medical Soc
This article reviews the mechanisms that lead to the development of Graves'
ophthalmopathy. A central feature in its development is autoimmunity that involves not only T …

Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells

M Bajzikova, J Kovarova, AR Coelho, S Boukalova… - Cell metabolism, 2019 - cell.com
Cancer cells without mitochondrial DNA (mtDNA) do not form tumors unless they
reconstitute oxidative phosphorylation (OXPHOS) by mitochondria acquired from host …

Protein therapeutics: a summary and pharmacological classification

B Leader, QJ Baca, DE Golan - Nature reviews Drug discovery, 2008 - nature.com
Once a rarely used subset of medical treatments, protein therapeutics have increased
dramatically in number and frequency of use since the introduction of the first recombinant …

Macrophages in inflammation

N Fujiwara, K Kobayashi - Current Drug Targets-Inflammation & …, 2005 - ingentaconnect.com
The inflammatory process is usually tightly regulated, involving both signals that initiate and
maintain inflammation and signals that shut the process down. An imbalance between the …

Cytokines in atherosclerosis: pathogenic and regulatory pathways

A Tedgui, Z Mallat - Physiological reviews, 2006 - journals.physiology.org
Atherosclerosis is a chronic disease of the arterial wall where both innate and adaptive
immunoinflammatory mechanisms are involved. Inflammation is central at all stages of …

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial …

SB Cohen, P Emery, MW Greenwald… - Arthritis & …, 2006 - Wiley Online Library
Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …